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Abstract 27 
Study design: Review Study 28 
Objectives: The identification of prognostic biomarkers of spinal cord injury (SCI) will help to 29 
assign spinal cord injured patients to the correct treatment and rehabilitation regimes. Further, the 30 
detection of biomarkers that might predict permanent neurological outcome would aid appropriate 31 
recruitment of patients into clinical trials. The objective of this review is to evaluate the current state-32 
of-play in this developing research field. 33 
Setting: Studies from multiple countries were included. 34 
Methods: We have completed a comprehensive literature review of all studies (to our knowledge) 35 
that have investigated prognostic biomarkers in either the blood or CSF of animals and humans 36 
following SCI.  37 
Results: Targeted and unbiased proteomic approaches have identified several putative prognostic 38 
biomarkers in CSF and blood. These proteins associate with cellular damage following SCI and 39 
include cellular components from neurons, oligodendrocytes and reactive astrocytes, i.e. 40 
neurofilament proteins, glial fibrillary acidic protein (GFAP), Tau, and S100 calcium binding protein 41 
β (S100β). Unbiased approaches have also identified microRNAs that are specific to SCI, as well as 42 
other cell damage associated proteins. 43 
Conclusions: The discovery and validation of stable, specific, sensitive and reproducible biomarkers 44 
of SCI is a new but rapidly expanding field of research. To date, very few studies have utilised 45 
unbiased approaches aimed at the discovery of biomarkers within the CSF or blood in this field, 46 
however some targeted approaches have been successfully used. Several studies using various animal 47 
models and some with small human patient cohorts have begun to pinpoint biomarkers in the CSF 48 
and blood with putative prognostic value. An increased sample size will be required to validate these 49 
biomarkers in the heterogeneous clinical setting. 50 
Keywords 51 
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1. Introduction 53 
There is now a vast and expanding body of literature describing different novel approaches for the 54 
treatment of spinal cord injury (SCI). Despite this, actions to treat and rehabilitate following SCI 55 
have not changed. Outside of clinical trials, SCI is typically managed either by surgical stabilisation 56 
or conservative management in the acute and subacute setting, followed by physiotherapy in the 57 
subacute and chronic phases of injury (1,2). It is clear that the SCI research field as a whole is 58 
experiencing a significant delay in the translation of new interventions into the clinic. There are 59 
many valid reasons why scientists and clinicians alike are cautious to translate new therapies into 60 
humans, particularly as setting up appropriate clinical trials to demonstrate safety and efficacy can be 61 
difficult (3). 62 
 63 
There is a growing appreciation for the benefit of using biomarkers to help introduce new treatments 64 
and improve strategies of care for SCI patients. We suggest there are several ways (diagnostic, 65 
prognostic and therapeutic) in which measuring biomarkers in the blood or CSF might complement 66 
current clinical measures, such as the American Spinal Injuries Association (ASIA) International 67 
Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scoring system and 68 
assessment of dry biomarkers such as magnetic resonance imaging (MRI) scans, to further the SCI 69 
field. Together a panel of biomarkers and neurological tests perhaps even including 70 
electrophysiological assessments may provide clinicians with a much clearer picture as to an 71 
individuals’ severity of neurologic impairment. 72 
 73 
Immediately following a SCI, besides those that have a complete AIS-A (equivalent to Frankel A) 74 
diagnosis where recovery of motor function, although possible (4), is relatively limited and 75 
predictable, the prognosis in the acute stage of SCI remains uncertain (5). For these patients, 76 
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knowing whether they will regain the ability to walk, irrespective of neurological, bladder or bowl 77 
function improvement, remains their key concern (6). Identification of a panel of biomarkers that 78 
could accurately predict an individuals’ ability to regain neurological, physical and autonomic 79 
function, could be of great psychological benefit to these patients. Furthermore, depending on the 80 
individuals’ prognosis, the treatment pathway could be tailored to ensure that optimal neurological 81 
and/or physical function is regained and that patient rehabilitative care is maintained until their best 82 
possible outcome is achieved.  83 
 84 
ISNCSCI diagnosis of a SCI can be delayed due to problems associated with poly-trauma 85 
stabilisation or a lack of SCI expertise at the treating hospital. Therefore a diagnostic CSF or blood 86 
test that can be used to assess the neurological state of these individuals may provide a quicker, 87 
cheaper and more accurate method, which will empower clinicians to stratify patients to the most 88 
suitable treatments for their needs. Additionally, as novel treatments to target the acute phase of SCI 89 
develop, quick and accurate diagnoses of patients who will be appropriate to recruit to these clinical 90 
trials will ensure studies are appropriately powered to assess efficacy. Despite prediction of 91 
neurological improvement having been the focus of a majority of biomarker studies, there is also 92 
value in the use of biomarkers to predict other long-term outcomes, such as neuropathic pain, for 93 
which early intervention studies could be implemented to try and prevent the onset of these 94 
conditions. 95 
 96 
Currently, in both routine clinical care and in clinical trials, the neurological condition of individuals 97 
is assessed by ISNCSCI grading and imaging modalities. Biomarkers that can easily be repeatedly 98 
measured within the blood or CSF of these individuals’ to determine progressive neurological 99 
condition would be highly beneficial, as it would allow rapid determination as to whether the patient 100 
was improving, worsening or showed sustained neurological stability in response to their current 101 
 5 
treatment; thus providing a biological surrogate outcome measure. Further, such biomarkers might 102 
indicate whether the patient has increased neurological plasticity in response to a treatment or 103 
rehabilitation regime. Finally, biomarkers released into the CSF and or blood, may provide a plethora 104 
of information as to the patients’ biological response to SCI. As discussed below, different biological 105 
responses to SCI may lead to specific molecules being released into the CSF or blood; these fluids 106 
may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the 107 
mechanisms underlying an individuals’ SCI.  Again, this could allow for personalised treatments to 108 
be provided to a patient that target their specific injury mechanisms and that can be used to assess 109 
their specific mechanistic responses. 110 
 111 
In recent years, scientists have started to take up the challenge of discovering and validating 112 
biomarkers in the blood and CSF that have prognostic value in accurately diagnosing complete or 113 
incomplete SCI and determining SCI progression. This review aims to present an overview of the 114 
current state of play in this emerging field. We will explain how the biological process of SCI may 115 
lead to the release of biomarkers of interest into the CSF and blood; the techniques that are 116 
commonly used to find and validate these markers, and the pre-clinical and clinical studies that have 117 
already begun to highlight biomarkers of interest. 118 
 119 
2. SCI and the release of biochemical biomarkers 120 
This section of the review aims to highlight some of the major processes that occur following a SCI, 121 
which could lead to biomarker release. It is still unclear how biomarkers from the spinal cord are 122 
released into the blood following injury; however, we suggest that their release is likely to be highly 123 
influenced by the specific type of injury sustained and the biochemical properties of the biomarkers 124 
in question. The majority of biomarkers which have already been studied in both pre-clinical and 125 
clinical studies have been identified from targeted biomarker identification processes, i.e. looking for 126 
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markers that are likely released based on the known biological processes/mechanisms that occur 127 
following SCI.  128 
 129 
2.1. Spinal cord tissue damage 130 
In both animal models of SCI and in the human situation, spinal cord traumas fall broadly into two 131 
categories: transection injuries, where the spinal cord is penetrated with a sharp force; and the more 132 
common contusion traumas, where the spinal cord is essentially crushed (7,8). Both types of injury 133 
result in a breach of the blood brain barrier (BBB) and either immediate primary or secondary 134 
damage to the neurons and glia of the spinal cord tracts. Rupture of these cell types results in the 135 
release of biomarkers, largely cellular components, which are specific in the indication of nervous 136 
tissue damage and include neurofilaments (NF) (9), Tau (10), neuron specific enolase (NSE) (11), 137 
S100 calcium-binding protein β (S100β) (11) and glial fibrillary acidic protein (GFAP) (9). These 138 
tissue specific biomarkers (discussed in greater detail below) hold great promise as they are typically 139 
released into the CSF then taken up into the blood stream, allowing for their detection local to the 140 
injury site and systemically. The quantity of these proteins in the CSF and blood might directly relate 141 
to the extent of neuronal or glial damage that has occurred following SCI (12,13).  142 
 143 
2.2 Inflammation  144 
In brief, the breakdown of the BBB allows for an influx of inflammatory cells into spinal cord 145 
tissues. Infiltrating leukocytes and resident microglia release proteolytic and oxidative enzymes, 146 
reactive oxygen species and an array of pro-inflammatory cytokines, including, for example, tumour 147 
necrosis factor-alpha (TNF-α) (14,15). This spike in acute phase pro-inflammatory molecules can be 148 
measured in human blood in the first 24h following injury (16). Caution must be taken when 149 
considering the blood at this stage however, as many of the abundant proteins that are seen acutely 150 
after injury may be a result of the systemic response to trauma and not SCI per se; study of animal 151 
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models where matched ‘sham’ injuries can be performed allows for the opportunity to establish 152 
which proteins are SCI specific. The pronounced acute pro-inflammatory response to injury induces 153 
a reactive process of secondary damage in the tissues that surround the original injury site, 154 
exacerbating neuronal damage and neurological dysfunction (14). This secondary damage cascade 155 
can continue for several weeks following SCI, contributing to an expanding matrix of proteins 156 
associated with neuronal and glial cell apoptosis, such as soluble CD95 ligand (sCD95L), an initiator 157 
of the Fas apoptotic pathway (17). 158 
 159 
2.3 Glial scarring 160 
Glial cell activation and hypertrophy leads to the formation of a glial scar in the subacute and chronic 161 
phases of SCI (18). Astrocytes become reactive and synthesise an extracellular matrix which is 162 
effective in restoring the BBB, but that coincidentally inhibits axonal regrowth (18). The most potent 163 
of these astrocyte associated nerve inhibitory molecules are the neural chondroitin sulphated 164 
proteoglycans (CSPGs) (19,20). Myelin damage associated molecules represent the other major 165 
nerve inhibitory molecules within the glial scar, these include myelin-associated glycoprotein 166 
(MAG), Nogo-A and oligodendrocyte-myelin glycoprotein (OMgp) (21). There is a vast body of 167 
literature which confirms that CSPGs, MAG, Nogo-A and OMgp can inhibit neurite outgrowth in 168 
vitro and axonal regrowth in vivo (22–28) and that treatments which specifically target these 169 
molecules promote functional recovery in SCI pre-clinical studies both individually (29,30) and in 170 
combination (31). However, there is little research exploring the utility of these molecules as 171 
prognostic biomarkers detectable in the CSF (32). Perhaps this is because we associate such 172 
molecules with the subacute or chronic phases of injury, when a stable neurology is much more 173 
likely. However, biomarkers, such as CPSGs that could be used to monitor any transition from the 174 
sub-acute to chronic phase of injury might aid clinicians in decisions regarding rehabilitation. 175 
 176 
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3. Detection of biomarkers for SCI using unbiased approaches 177 
Although it would be ideal, biomarkers of injury or disease are rarely either “detectable” or 178 
“undetectable”. In most cases, biomarkers vary in expression levels under different conditions. It is 179 
important, therefore, to have specific and sensitive methods to quantify these changes. Typically, 180 
immunoassays have been the method of choice for studies that aimed to evaluate SCI biomarkers 181 
within the blood or CSF. The enzyme-linked immunosorbent assay (ELISA) is the most commonly 182 
employed assay to date, and both homemade and commercial ELISA kits have been utilised. 183 
Automated immunoassay systems are available for some potential biomarkers e.g. the Liaison 184 
automatic analyser for S100β and NSE (9,33), but it seems unlikely that the use of automated 185 
systems will become widespread until such biomarkers have become fully validated for routine 186 
clinical use. 187 
 188 
The vast majority of studies aimed at finding new biomarkers for SCI have been based on a 189 
hypothesis about a particular protein of interest. Shaw et al. (2005), for example, proposed that, due 190 
to their high abundance in neurons, detection of NF proteins in CSF and/or serum is highly likely to 191 
indicate neuronal damage (34). Of the three NF subunits (i.e. light (L), medium (M) and heavy (H)), 192 
phosphorylated NF-H (pNF-H) was thought likely to be the most readily detectable in serum or CSF 193 
following neurological injury because of its relative resistance to protease degradation (34). The 194 
results from this hypothesis-driven study formed the basis of several further studies to evaluate the 195 
prognostic potential of this biomarker following SCI (9,35). 196 
 197 
Surprisingly very few studies, however, have employed higher-throughput techniques to identify new 198 
biomarkers of SCI. A search of PubMed using the terms “proteomics AND spinal cord injury” and 199 
“biomarkers AND spinal cord injury” identified just four publications in which the aim of the study 200 
was to identify new peripherally accessible biomarkers of SCI (Table 1). Even more surprisingly, 201 
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given the popularity in other fields of biomedical research (recently reviewed by Crutchfield et al. 202 
(2016) (36)), only two of these studies reported the use of unbiased quantitative proteomic techniques 203 
to find novel biomarkers of SCI in the CSF or blood, while the remaining two studies employed 204 
relatively low-throughput array technology. Notwithstanding the limitations of array technology-205 
based screening, several potential SCI biomarkers were identified in this way. Using a 34-cytokine 206 
sandwich ELISA microarray, Light et al. (2012), identified increased levels of matrix 207 
metalloproteinase-8 protein in CSF samples taken from adult rats at 12 days post-SCI (37), and 208 
Hachisuka et al. (2014) found increased serum levels of the microRNAs miR-9, miR-219 and miR-209 
384-5 in mice at 12hrs after contusion SCI (n=8) compared to sham injury (n=8) using a low-density 210 
microarray platform (Table 1) (38). 211 
 212 
Despite some findings using array technology based screening, as expected, the unbiased quantitative 213 
proteomic comparisons were more fruitful in terms of the numbers of potential biomarkers that were 214 
identified. Using difference gel electrophoresis (DIGE) and mass spectrometry (MS) analysis to 215 
compare CSF from patients at 1-8 days post SCI, Sengupta et al. (2014) identified eight proteins that 216 
were differentially expressed between complete and incomplete injured patients (39) (Table 1). Using 217 
a high-throughput label-free liquid chromatography-MS/MS quantitative proteomics technique, 218 
Lubienicka et al. (2011) compared CSF taken from rats at 24hrs post-SCI and identified 42 putative 219 
biomarkers; 10 of which are indicative of SCI severity (40) (Table 1). Moghieb et al. (2016) also 220 
used MS to identify biomarkers of SCI, however, their approach was not to initially look for CSF or 221 
blood biomarkers, instead they assessed protein changes within spinal cord tissue segments, of which 222 
Transferrin, Triosephosphate Isomerase 1, Cathepsin D and Phosphoprotein Enriched In Astrocytes 223 
15 (PEA-15) were confirmed as altered in human SCI CSF (41).  224 
 225 
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Despite proteomics providing a popular platform for novel biomarker identification in many fields of 226 
study, other high-throughput techniques, such as lipidomics and metabolomics are also valuable in 227 
biomarker identification (36). As is the case with proteomics, only a limited number of published 228 
studies have utilised these approaches to elucidate biomarkers for SCI. Xu et al. (2015) 229 
demonstrated, by assessment of lipidomic analysis of polyunsaturated fatty-acid containing 230 
phosphatidylcholines within the spinal cord tissue, that spatiotemporal expression of one of these 231 
phosphatidylcholines matched with reactive microglia and astrocyte activity (42). Although not 232 
directly relevant to CSF or blood biomarkers, Xu et als’ study indicates that lipidomic analysis of 233 
these fluids may clarify the role of lipid metabolism and damage of the cell membrane following SCI 234 
(42). There is also a need to further study the metabolome of CSF and/or blood of SCI patients, as 235 
this represents the end-point of all gene, transcript and protein interactions (43). Peng et al. (2014) 236 
published a comprehensive paper highlighting that metabolomic analysis of plasma from SCI rats led 237 
to identification of a panel of metabolites that could be used to selectively determine injured 238 
compared to sham injured animals, based on metabolite measurements alone (44). Analysis of these 239 
metabolites within the plasma of human SCI patients’ is required to see if these findings translate to 240 
man and further similar metabolomic studies of human blood samples may also pinpoint other 241 
biomarkers.  242 
 243 
4. Identifying biomarkers in the CSF and blood of pre-clinical models and human SCI patients 244 
using ‘targeted’ approaches 245 
As discussed previously, the vast majority of studies that aimed to assess CSF or blood biomarkers of 246 
SCI have done so based on ‘targeted’ proteins that are known to relate to the biological processes that 247 
occur following a SCI. Many of these biomarkers have so far been assessed in pre-clinical models of 248 
SCI. Pre-clinical models are highly controllable and provide the opportunity to measure differences 249 
in the concentration of a biomarker in animals with a SCI and sham-injured animals (a comparison 250 
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not possible using human subjects). These models also allow for longitudinal analyses comparable to 251 
acute, sub-acute and chronic timeframes post-SCI. It is, however, difficult to relate the phases of 252 
injury in rodent models to that of the human situation, particularly as much depends on which of the 253 
models of injury are used, and as such there is no published consensus of opinion.  254 
 255 
Causes of human SCI are wide-ranging therefore several different animal models have been 256 
generated in an attempt to account for this diversity, although it is extremely unlikely that any animal 257 
model will ever be able to replicate the complexity of human injury. As discussed previously, the two 258 
major categories of SCI are sharp force or “stab” lesions and contusive injuries. In rodent models, 259 
contusion injuries are most commonly induced using blunt force impact devices (45), in which 260 
calibrated weights are dropped onto an impounder which is rested on the surgically exposed spinal 261 
cord (46,47). This technique allows for varying degrees of injury depending on the amount of force 262 
used. Other methods of inducing an injury include the use of an aneurysm clip or calibrated forceps 263 
to compress the cord for a set time-period (48,49). Contusion injuries are commonly used as models 264 
of incomplete injury, whereas to study complete injury, complete transection of the spinal cord is 265 
often carried out using either microscissors or a scalpel blade cutting all of the spinal cord tracts by 266 
surgical incision and under visual control using suction to visually check for a complete injury 267 
(50,51).  268 
 269 
Both human and pre-clinical models have been utilised to identify potential biomarkers of SCI 270 
progression. Tables 2 and 3 detail all of the studies (to our knowledge) that have assessed CSF and/or 271 
blood biomarkers of SCI in pre-clinical and human models, respectively. Here we discuss the leading 272 
candidate biomarkers of SCI severity and prognosis identified thus far, based on their known 273 
relevance to the biological processes that result following SCI.  274 
 275 
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4.1 Neurofilament proteins 276 
Neurofilament proteins (NF) are the most abundant proteins in the neuronal cytoskeleton (52). They 277 
interact with other cytoskeletal proteins to regulate axonal transport and neuronal signalling (52). The 278 
presence of extracellular NF proteins is an indication of axonal damage and NF accumulation is seen 279 
in several neurological diseases (53) including multiple sclerosis (54–56), amyotrophic lateral 280 
sclerosis (54,57) and traumatic brain injury (TBI) (58). NF proteins have long half-lives (3 weeks and 281 
2.5 months for NF-L and pNF-H, respectively) (59,60) and  pNF-H, in particular, is highly resistant 282 
to breakdown by calpain and other systemic proteases (32). These proteins, therefore, provide 283 
attractive candidate biomarkers for SCI as they are not broken down before detection would be 284 
possible. The phosphorylated form of NF-H (pNF-H) (9,34) and NF-L (57,58) are the two subunits 285 
which have been most widely considered as biomarkers for SCI and shall be discussed in more detail 286 
below.  287 
4.1.1 Neurofilament- heavy chain (NF-H) 288 
SCI has been shown to result in increased levels of pNF-H in the CSF and blood of humans, rats and 289 
canines (9,34,61,62), as assessed using ELISA. In rat serum for example, no pNF-H can be detected, 290 
using ELISA, in uninjured and sham injured animals, however, severe experimental SCI results in 291 
high levels of measurable pNF-H (34). A detailed study of serum pNF-H concentrations (again 292 
assessed using ELISA) in rats with contusion (n=8) and spinal hemisection (n=13) injuries resulted in 293 
biphasic pNF-H being detectable in the late acute, sub-acute and chronic phases of both injuries (34). 294 
A sharp peak in pNF-H was observed at 16h post-SCI whilst maximal serum concentrations were 295 
seen at 3 days post-SCI, returning to baseline levels at approximately 18 days (34). 296 
Animal studies have also revealed that blood pNF-H levels can indicate disease severity and directly 297 
relate to functional outcome. Nishida et al. (2012) demonstrated that in dogs with degenerative disc 298 
disease (DDD; n=60), pNF-H levels rose incrementally with the grade of injury severity observed 299 
(62). This study also demonstrated that those animals with the highest serum pNF-H levels at 300 
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veterinary presentation post-SCI were not able to regain the ability to walk following surgery (62). 301 
Ueno et al. (2011) also demonstrated a negative correlation (r -0.78) between rat plasma pNF-H 302 
levels at 3 days post SCI and hindlimb function at 28 days post SCI (assessed using Basso, Beattie, 303 
Breshnahan (BBB) score) (61).  304 
 305 
A small cohort of human studies also indicates that there is a correlation between pNF-H and disease 306 
state. In the CSF of SCI patients (n=15), pNF-H concentrations are higher at 6 to 48h post trauma 307 
compared to that in uninjured individuals (n=6) (35). Further, Pouw et al. (2014), found that NF-H 308 
concentrations in CSF were significantly greater in motor complete (n=9) patients compared to motor 309 
incomplete patients (n=7) (9).  In a recent, slightly larger study, pNF-H levels in the serum of SCI 310 
trauma patients (n=26) were significantly greater compared to controls with spinal fracture but no 311 
spinal cord trauma (n=9) at 24h and 48h post-injury (63). These studies indicate that the 312 
measurement of pNF-H within the CSF and peripheral blood has potential as a prognostic biomarker 313 
in the acute phase of SCI.  314 
 315 
4.1.2 Neurofilament- light chain (NF-L) 316 
Levels of NF-L have been assessed in both the CSF and serum of SCI patients (64,65). Guez et al. 317 
(2003) found there to be increased levels of NF-L in CSF following SCI compared to uninjured and 318 
whiplash injured patients (64). This study also demonstrated that for a patient with complete injury 319 
and complete tetraparesis with no long term neurological improvement, NF-L levels were 10-fold 320 
higher than in a complete injured patient who improved to AIS-D by 15-months post-injury (64). 321 
This indicates that NF-L also may have utility as a biomarker of a patients’ prognosis. In the later, 322 
larger study, NF-L correlation with SCI severity and neurological outcome was confirmed (65). NF-323 
L concentrations were found to be higher in the motor complete (n=13) patients (70 pg/mL) and 324 
motor incomplete (n=10) patients compared to others with central cord syndrome (n=4; 6 pg/mL) and 325 
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uninjured controls (n=67; 5pg/mL).  Unlike pNF-H, the potential of NF-L as a biomarker for SCI has 326 
not been strengthened by pre-clinical studies. Despite this, NF-L is shown in preliminary human 327 
studies to have potential value in the classification of patients with or without capacity for 328 
neurological improvement. 329 
 330 
4.2 Tau 331 
Tau proteins are microtubule stabilising proteins that are highly abundant in neurons (66–68). Like 332 
NFs, these proteins function to maintain axonal transport and neuronal transmission (69). Expression 333 
of Tau proteins within the CSF or blood of animals and humans is likely indicative of neuronal 334 
damage, as these proteins are not usually secreted (10). Although several investigations into the use 335 
of Tau as a biomarker for neurodegenerative diseases, such as conversion from mild cognitive 336 
impairment to Alzheimer’s disease (70), have been described, there are fewer studies examining 337 
these proteins as putative biomarkers for SCI.  338 
 339 
There are no publications of SCI research into Tau as a biomarker in typical laboratory animal model 340 
of SCI, however, veterinary studies looking to use Tau as a marker of SCI in dogs following IVD 341 
herniation (IVDH) suggest that an acute rise in Tau levels might indicate decreased capacity for 342 
functional recovery (71). In a study of 51 dogs, CSF was collected immediately upon admission to 343 
the veterinary hospital (71). As well as Tau levels increasing with injury severity (higher in 344 
incomplete injured compared to healthy animals and in complete compared to incomplete injured 345 
animals), the highest levels of CSF Tau protein corresponded with those dogs which took the longest 346 
time to recover function (71).  347 
 348 
In human studies, the consequence of SCI on Tau levels is not overly clear. Pouw et al. (2014) 349 
assessed Tau levels in CSF collected within 24h of injury in motor complete and motor incomplete 350 
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patients and found no significant differences associated with the degree of SCI (9). In contrast, two 351 
studies from Kwon et al. (2010 & 2016) found that in CSF collected from patients within 48h of 352 
injury with complete or incomplete SCI, Tau concentrations were significantly elevated in a severity-353 
dependent manner (72,73). Interestingly, increased CSF Tau concentrations found between complete 354 
and incomplete injured individuals was observed at the 24h time-point (72,73), which in the Pouw et 355 
al (2014) study showed no significant difference. This discrepancy between the studies is probably 356 
due to a difference in patient numbers (Pouw et al. (2014), n=16; Kwon et al. (2010), n=27; Kwon et 357 
al. (2016), n=50) and possibly a difference in time between injury and start of CSF collection, as 358 
Pouw et al. (2014) started collecting CSF within 24h of injury (9), whereas Kwon et al (2010 &2016) 359 
started up to 48h after injury (72,73). In combination with other markers, Tau can predict initial AIS 360 
grade and if its’ baseline measurement is low it can predict an improvement in AIS grade by 6 361 
months post-injury (73). 362 
  363 
Kwon et al. (2010) plotted Tau concentrations within the CSF from 8 to 120 hours following a SCI 364 
(72). Interestingly, the concentration of Tau remained higher in AIS-A patients compared to AIS-B 365 
and AIS-C graded patients through to 48h after injury however no difference in CSF concentrations 366 
of Tau existed between 48 and 120h post-injury (72). This observation highlights the dynamic nature 367 
of the biological processes that follow a SCI and the importance of assessing candidate biomarkers 368 
over time to ensure the most appropriate time is selected for measurement of differences in 369 
biomarkers.  370 
 371 
4.3 Neuron Specific Enolase (NSE) 372 
Neuron specific enolase (NSE) is the dimeric neuronal form of the glycolytic enzyme enolase. This 373 
enzyme is a marker of ischemic brain damage (74) and although it only has a short biologic half-life 374 
(≤ 24h) (75), NSE holds promise as an acute indicator of neuronal damage. 375 
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 376 
NSE levels are elevated in the CSF, plasma (76) and serum (77) of rats in the acute phase of SCI. 377 
Further, NSE levels continue to be elevated at 24h post-injury in the serum of SCI compared to sham 378 
injured rats (77), however, assessment in CSF or plasma for time-periods greater than 24h post-SCI 379 
has not been evaluated in rodent models. Again, in humans NSE has only been assessed in the acute 380 
period post-injury (≤24h) (9,78) and measurement outside of this timeframe may be inappropriate 381 
with respect to the short half-life of this protein.  382 
 383 
Nonetheless, NSE has been shown to have potential as an indicator of SCI severity. In rats with mild 384 
(n=20), moderate (n=20) and severe (n=20) spinal cord contusion injuries, 6h measurements of CSF 385 
and plasma showed significantly greater levels of NSE in moderately and severely injured rats (with 386 
greater NSE levels in the severely vs. moderately injured) compared to mildly injured animals (77). 387 
In humans, higher NSE concentrations were observed in the CSF of motor complete (n=9) compared 388 
to motor incomplete patients (n=7)(9). Results from Wolf et al. (2014) however, suggest that 389 
measurement of NSE in the serum of patients may be inappropriate to assess disease severity, as 390 
serum NSE concentrations within 24h of injury were no different when compared to vertebral injured 391 
patients with (n=12) or without (n=22) neurological deficit (78). 392 
 393 
4.4 S100 calcium binding protein β (S100β) 394 
S100β is a glial specific S100 protein that is released into blood and CSF during the acute phase of 395 
brain injury (79). S100 is involved in a diverse range of functions including calcium homeostasis, 396 
enzyme activity and metabolism, cell proliferation and differentiation (80). Measurement of S100β 397 
has potential as an acute marker of SCI, as it is significantly increased in the blood (76,77,81) and 398 
CSF (76) of rats at 6h after severe contusion injury compared to sham injury. In the human acute 399 
setting (<48h), S100β is also increased in the serum of patients with vertebral spine fractures 400 
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(mean=0.77 μg/L; n=34) compared to uninjured patients (0.14 μg/L; n=29) (78) and in the CSF of 401 
AIS-A grade patients compared to those with an AIS-B or C ISNCSCI score (73). Further, Pouw et 402 
al. (2014) showed there to be higher levels of detectable S100β in the CSF at 24h in those patients 403 
who did not show improvement in AIS score at 6 or 12 months post-injury (9). This finding is 404 
corroborated by Kwon et al. (2016), who showed decreased S100β concentrations within the CSF up 405 
to 48h after injury in SCI patients who demonstrated an improvement in AIS grade by 6 months post-406 
injury (73). Therefore, early acute phase assessment of S100β within the CSF could provide a 407 
predictive biomarker of neurological improvement.  408 
 409 
 Assessment of serum and CSF S100β concentrations outside of the acute setting has not yet been 410 
studied. However, results from animal studies demonstrate that by 24h post-injury, S100β levels are 411 
unaltered in response to SCI (77), perhaps limiting the potential of this biomarker for clinical use to 412 
the acute setting only. In addition, S100 has been measured in conjunction with NSE in two animal 413 
studies (76,77) which indicated that co-measurement, rather than singular measurement of these 414 
markers in the acute stages of injury is a more robust prognostic indicator of SCI severity. 415 
 416 
4.5 Glial Fibrillary Acidic Protein (GFAP) 417 
The intermediate filament protein found in astroglia, glial fibrillary acidic protein (GFAP), is a 418 
widely acknowledged biomarker of severe brain damage resulting from haemorrhage or serious 419 
trauma, with both serum and CSF levels being higher in patients with traumatic brain injury (TBI) 420 
compared to uninjured controls (82). Despite the fact that GFAP is an established marker of neural 421 
injury in other fields, very few studies have investigated its potential as a biomarker of SCI.  In a 422 
small preliminary study, Yokobori et al. (2015), demonstrated higher GFAP levels in the CSF of rats 423 
in the acute phase following contusion injury (n=4) compared to sham injured animals (n=4) (83). 424 
Ahadi et al. (2015) (63) demonstrated that GFAP is also increased in the serum of human acute SCI 425 
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patients (n=26) compared to uninjured controls (n=9). Further, Pouw et al. (2014) and Kwon et al. 426 
(2016) confirmed that CSF GFAP concentrations were higher in complete vs. incomplete SCI 427 
patients and hence that GFAP concentrations appear to be associated with SCI severity (9,73). 428 
Measurement of CSF GFAP within 48h of injury has also been used, in combination with other 429 
inflammatory and structural markers, to predict which AIS-A patients would show an improvement 430 
in AIS score by 6 months post-injury, with an 83% success rate (73). Therefore acute assessment of 431 
CSF GFAP may provide a predictive biomarker of neurological improvement.  Longitudinal analyses 432 
by Yokobori et al (2015) (83) showed maximal GFAP levels in CSF in rats at 4h post SCI, with CSF 433 
concentrations decreasing sequentially at 24h and 48h after injury (83); further studies are required to 434 
ascertain GFAP levels in the chronic phase of SCI.  435 
4.6 Pro-inflammatory cytokines 436 
Unsurprisingly, SCI can lead to the release of pro-inflammatory cytokines across the BBB. 437 
Therefore, several researchers have investigated whether concentrations of these cytokines in the 438 
blood of SCI patients relate to neurological outcome. TNF-α is a cytokine involved in the acute phase 439 
of pro-inflammatory signalling and is increased in the serum of SCI patients (n=56) compared to 440 
uninjured controls (n=35) in the sub-acute phase (2-52 weeks) (84). This pattern of increased serum 441 
TNF-α concentrations following SCI (n=6) compared to sham injury is maintained in rats (85). 442 
Moreover, SCI patients who show improved neurological function, had lower TNF-α at 9h, 443 
compared to SCI patients who failed to improve neurologically (16). Interleukin 1 beta (IL-1β) is a 444 
key moderator of proliferation and inflammation that is thought to be vital for the formation of the 445 
glial scar (86). Ischaemia/ reperfusion SCI in rats (n=6) resulted in increased serum IL-1β levels at 446 
both 24 and 48 hrs after injury when compared to sham injured rats (n=6) (85). Despite human CSF 447 
or blood measurements of IL-1β not having been compared between SCI and uninjured individuals, 448 
baseline assessment (4 hrs after hospital admission) of this cytokine in serum showed no difference 449 
between patients who did or did not show an improvement in AIS score (16). Between weeks 1 and 4 450 
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after injury, however, serum IL-1β concentrations decreased significantly, only in patients who did 451 
not show an improvement in AIS score (16), indicating that maintenance of higher serum IL-1β 452 
concentrations may lead to improved neurological outcome. Previously, a pre-clinical model has also 453 
indicated that Interleukin 6 (IL-6) may be a suitable blood biomarker to diagnose SCI, as at both 24 454 
and 48 hrs after SCI serum concentrations of IL-6 were greater when compared to sham injured 455 
rodents (85). More recently, Kwon et al (2016) have demonstrated CSF concentrations of pro-456 
inflammatory cytokines IL-6 and Interleukin 8 (IL-8) can be assessed in the acute phase of human 457 
injury (≤48h) to both determine injury severity and to predict neurological improvement from an 458 
AIS-A to either AIS-B or C grade by 6 months post-injury (73). 459 
 460 
4.7 Soluble CD95 ligand (sCD95L) 461 
During the acute and subacute phase of SCI, neuronal damage via apoptosis is prolific. The Fas 462 
ligand receptor system is key in driving this apoptotic response (87). Soluble CD95 ligand 463 
(sCD95L/Fas-L) is a cleavage product of the type II transmembrane protein CD95L (17), which 464 
when activated and bound to CD95 (Fas) can initiate the Fas apoptotic pathway. sCD95L induces 465 
neutrophil secretion of pro-inflammatory chemokines (88). Although blocking the CD95 pathway in 466 
SCI rats improved functional outcome, assessment of human blood sCD95L via ELISA, showed no 467 
difference in concentration when comparing complete vs. incomplete injured patients at 4h and 12 468 
weeks post injury (89,90). It is of note, however, that in these human studies no uninjured control 469 
group was included; as such it is difficult to determine whether sCD95L concentration alters at all in 470 
response to SCI. 471 
 472 
5. Discussion 473 
This review has aimed to evaluate biomarkers in the CSF and/or blood that are currently under 474 
assessment as potential indicators of SCI diagnosis, severity and likely neurological outcome in 475 
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preclinical and clinical studies. These studies have aimed to establish whether biomarker detection in 476 
CSF and blood is possible, to determine the longevity and stability of these biomarkers in each body 477 
fluid, and their value in predicting neurological outcome, as assessed by ISNCSCI score. All of the 478 
studies described are either in the pre-clinical stages of biomarker validation or have been undertaken 479 
only in a small number of human patients. Pre-clinical models provide an invaluable tool in which 480 
biomarker characteristics can be studied without the added complexity of clinical human-to-human 481 
SCI variability. Importantly, the use of sham-injured animals for comparison ensures that biomarkers 482 
that are specific to SCI are identified, as sham-injury can account for systemic responses, such as 483 
systemic inflammation, that may occur in relation to the ‘trauma’ of sham injury. In human studies 484 
that have compared biomarkers between SCI and healthy ‘controls’ (91), such healthy individuals are 485 
unlikely to demonstrate any of the systemic biological responses that may exist, therefore some of 486 
the protein differences observed between the injured and control groups are likely to be non-specific 487 
to SCI. Access to appropriate human ‘sham injury controls’, where the same level and type of trauma 488 
is observed along with matched patient demographics but without any injury to the spinal cord tissue 489 
is impossible to obtain. Guez et al. (2003), however, have assessed the utility of comparing SCI 490 
patients to individuals who had severe whiplash as a form of human ‘sham’ injured control. The 491 
majority of candidate biomarkers in the described literature represent neural structural proteins which 492 
are likely to be damaged following SCI and released into the CSF and blood following disruption of 493 
the BBB. A cautionary aspect to consider for these SCI biomarkers is that some are known to 494 
increase in the CSF and blood of individuals with brain injury or nervous system disease 495 
(58,74,79,82); these confounding factors should be taken into consideration when exploring their 496 
utility in the clinic, especially in incidences of polytrauma. Further, some of the biomarkers that have 497 
indicated potential in SCI biomarker development have a short half-life (e.g. NSE), therefore 498 
accurate measurement of these may need to be carried out immediately after injury. Unfortunately, 499 
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the assessment of SCI biomarkers in the acute setting (<24h) might not always be possible, 500 
particularly in complex polytrauma cases where patient stabilisation is the priority. 501 
 502 
Several of the studies included in this review have assessed biomarkers solely within the CSF. It is 503 
intuitive to think that body fluids local to the injury site will contain the highest concentration of SCI 504 
specific molecules, metabolites or proteins. This has been confirmed by studies that have directly 505 
compared human biomarker concentrations in matched CSF and blood samples, which have 506 
demonstrated that acutely after injury (≤48h) concentrations of IL-6, IL-8, MCP-1, Tau, S100β and 507 
GFAP were at least 10 fold higher in the CSF compared to the blood (72); much higher CSF 508 
concentrations of biomarkers, including GFAP, were also demonstrated by Yokobori et al. (2015) 509 
(83). The collection of CSF from SCI patients however, increases their risk of infection of the 510 
meninges and has cost implications for the health service provider (92). Alternatively, if biomarkers 511 
can be identified systemically, the collection and analysis of peripheral blood would represent a less 512 
risky and more cost-effective approach. Therefore, there is benefit in pursuing techniques that are 513 
sensitive enough to detect differences in biomarker concentrations in blood, however, initial 514 
assessment of potential biomarkers may best be carried out in CSF where more apparent changes are 515 
likely to be noted. 516 
 517 
The majority of published studies that have assessed blood or CSF biomarkers in human SCI patients 518 
have assessed the effectiveness of a biomarker based on its ability to predict or correspond to 519 
ISNCSCI score. However, it may be that other measures of progression, such as improvements in 520 
hand grasping, medical imaging or electrophysiology provide more subtle improvements, which 521 
could more easily be unpicked by a difference in biomarkers. 522 
 523 
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The use of unbiased approaches to screen for putative biomarkers of SCI progression in CSF and 524 
blood, for example quantitative proteomic approaches, have so far been largely overlooked, but are 525 
likely to yield the greatest number of novel biomarker targets. The limited proteomic analyses of 526 
CSF from SCI patients that exists provides a benchmark for the number of novel candidates that can 527 
be identified (41), however, there is currently a lack of any essential follow-on validation via 528 
quantitative western blot or ELISA. An alternative approach to identifying novel biomarkers using a 529 
high-throughput approach, may be to assess protein changes within the spinal cord tissue and then 530 
evaluate whether these changes are reflected in the CSF or bloods, as could be demonstrated by 531 
Moghieb et al. (2016) (41). Alternatively, as bioinformatic approaches aimed at interpreting large 532 
proteomic datasets improve, initial in silico validation of the candidate biomarkers might be possible 533 
as an interim step before completing costly quantitative validation; an approach which has been 534 
effective in Alzheimer’s disease (93). 535 
 536 
In this review, we have evaluated the current state-of-play in the CSF and/or blood biomarkers of 537 
SCI research landscape, this review highlights some of the potential pitfalls which need to be 538 
overcome to ensure the clinical utility of biomarker candidates, such as accounting for polytrauma 539 
and delayed SCI diagnoses. In addition, it is clear that further investigation is required, to include 540 
much larger cohorts of human participants with a diverse range of injuries in order to confirm the 541 
clinical validity of the preliminary biomarker findings described. The need to identify and validate 542 
novel prognostic biomarkers that can be measured within the blood or CSF, for the assessment of 543 
SCI progression using unbiased approaches has also been discussed. 544 
 545 
It is highly unlikely that a single biomarker measurement will ever be used on its own to accurately 546 
predict SCI recovery in the clinic. We suggest that demographic and injury associated risk factors as 547 
well as the evaluation of ‘dry’ biomarkers i.e. radiological imaging modalities and 548 
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electrophysiological measurements in combination with the quantitation of several validated CSF 549 
and/or blood biomarkers will ultimately be used to provide a ‘risk of SCI progression’ index. Such a 550 
prognostic risk index would greatly advance the clinical management of SCI patients, reducing 551 
uncertainty for both patients and health care providers in the acute SCI setting and providing 552 
confidence in neurological stability prior to the recruitment of SCI patients into clinical trials. 553 
 554 
Finally, this review highlights the fact that very few studies have been published to identify 555 
biomarkers for other uses in the SCI field. Undoubtedly, biomarkers that could be used in clinical 556 
trials that aim to target specific disease mechanisms, such as remyelination, would be invaluable for 557 
assessing efficacy of a particular treatment and the mechanism of interest. Further, biomarkers that 558 
could be used to identify patients who will develop other long-term problems, such as neuropathic 559 
pain would also be advantageous for the stratification of patients to particular treatment.560 
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Reference Injury Type Sample 
numbers 
Species Sample Time of 
sampling 
(after SCI) 
Method of Biomarker 
screening 
Candidate Biomarkers 
Light et al., 
2012 (37) 
Contusion 
Sham 
n=4 
n=4 
Rat CSF 12 days Cytokine ELISA microarray Matrix Metalloprotease-8 
Thymus Chemokine-1 
Hachisuka et 
al., 2014 (38) 
Contusion (mild) 
Contusion (severe) 
Sham  
Untreated 
n=8 
n=8 
n=8 
n=8 
Mouse Serum 12h Taq-man low density array miR-219 
miR-384-5p 
miR-9 
Sengupta et al., 
2014 (39) 
 
Complete 
Incomplete 
 
 
Complete 
Incomplete 
n=7 
n=8 
 
 
n=3 
n=3 
Human CSF 1-8 days (acute) 
 
 
15-60 days 
(sub-acute) 
Difference gel electrophoresis 
(DIGE) and matrix assisted 
laser desorption/ ionisation- 
mass spectrometry (MALDI-
MS) 
GTF3C5 
HP 
IGHG2 
IGHG4 
ALB 
TF 
AZGP1 
APOH 
Lubienicka et 
al., 2011 (40) 
Contusion (moderate) 
Contusion (severe) 
Sham 
n= 9 
 
n= 9 
n= 9 
Rat CSF 24h Liquid chromatography-mass 
spectrometry (LC-MS/MS) 
YWHAG 
ORM1 
A1M 
A2M 
APOA1 
APOH 
B2M 
CA1 
CA2 
C3 
C1 
CRP 
FAM3C 
GPX3 
ITIH4 
ITIH3 
LASMP 
F11R 
KNG1 
LDHA 
IGKC 
NBL1 
SCG5 
PRDX2 
PZP 
ZMYND8 
S100A8 
F2 
SCG3 
SERPINC1 
CDH13 
MAP1 
YWHAZ  
 
Table 1 Candidate blood and/or CSF biomarkers for SCI identified from high-throughput techniques 
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Reference Biomarker Injury type Sample  
numbers 
Species Sample  Time of 
sampling 
 (after 
SCI) 
Findings 
Ueno et al., 
2011 (61) 
pNF-H Moderate 
contusion 
n=4 Rat Plasma 1, 2, 3, 4 
days 
Investigated if minocycline treatment could improve recovery 
following SCI by looking at pNF-H as a potential biomarker.  
pNF-H was detectable from 1 day post SCI, with levels peaking at 3 
days.   
pNF-H levels were lower in rats which had improved hindlimb 
function (BBB score).  
A negative correlation between pNF-H level at 3 days post SCI and 
BBB score at 28 days post injury existed. 
Nishida et al., 
2012 (62) 
NF-H Paraplegia with 
IVDH 
n=60 
control: n=6 
Dog Serum 1-3 days pNF-H was higher in animals with worse paraplegia (grade 5 vs. 
grade 4).  
Eight dogs with the highest pNF-H levels were unable to walk 
following surgery. 
Shaw et al., 
2005 (34) 
pNF-H Contusion 
Spinal 
hemisection 
n=8 
n=13 
Rat Serum 5, 2, 8, 16, 
24h 
2-21 days 
Increased pNF-H in SCI (contusion and spinal hemisection) injured 
vs. sham injured.  
pNF-H increased in the first few hours of injury and peaked at 16h 
post SCI.  
pNF-H levels had a second high peak observed at 3 day post SCI, 
before returning to baseline levels at 18 days post SCI. 
Roerig et al., 
2013 (71) 
Tau IVDH n=51 Dog CSF At time of 
veterinary 
admission 
Tau levels were increased in dogs with motor complete injury 
compared to healthy or motor incomplete injured dogs.  
Dogs which improved at least one neurological grade within a week 
had lower tau concentrations than those that took longer to recover. 
Loy et al., 
2005 (77) 
NSE; S00β Moderate 
contusion 
Severe contusion 
n=12 
n=10 
Rat Serum 6, 24h Significantly higher serum NSE levels were noted at 6h and 24h 
following SCI compared to sham injured animals.  
Significantly higher serum S100β levels at 6h in severely injured 
rats.  
S100β levels were not significantly different whn comparing SCI 
and sham injured rats at 24h.    
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Cao et al., 
2008 (76) 
NSE; S100β Mild contusion 
Moderate 
contusion 
Severe contusion 
n=20 
n=20 
n=20 
Rat CSF;Sru
m 
30 mins 
2,6,12,24h 
Significant increase in NSE and S100β levels in both serum and 
CSF from 2h post SCI compared to sham injury.  
At 6h post SCI, CSF and plasma NSE and S100β were significantly 
higher in moderate and severely injured rats compared tomldly 
injured rats and were significantly higherin severely injured rats 
compared to moderatel injured rats. 
Ma et al., 2001 
(81) 
S100 Spinal 
compression 
n=40 
control: 
n=24 
Rat Serum 2, 6, 13, 
24h 
3, 6, 10 
days 
Serum S100 increased within 3h after injury in the SCI rats. 
Levels of serum S100 peaked at 3h, 12h and 3 days after SCI and 
was significantly higher than levels in serum of sham injured rats at 
all three time points tested. 
Yokobori et 
al., 2015 (83) 
GFAP; 
SBDP120; 
SPDP145 
Contusion n=4 Rat CSF 4, 24, 48h GFAP and UCH-L1 levels in the CSF were increased at 4h, 24h, 
and 48h post SCI compared to sham injury.  
CSF GFAP levels were highest at 4h post injury, then decreased at 
24h and 48h.  
UCH-L1 was increased at 4h but not 24h or 48h after SCI when 
compared to sham injured animals. 
Hasturk et al., 
2009 (85) 
TNF-α 
IL-1β 
IL-6 
Spinal ischemia/ 
reperfusion 
n=6 Rat Serum 24, 48h Serum TNF-α, IL-1β and IL-6 was elevated following ischemia 
reperfusion injury compared to sham injury at 24 and 48 hrs. 
None of the cytokines showed altered abundance at 24 compared to 
4 hr in injured rats.  
Hachisuka et 
al., 2014 (38) 
miRNA Mild contusion 
Moderate 
contusion 
n=8 
n=8 
Mice Serum 3, 12, 24h 
3, 5, 7, 14, 
21, 28, 35, 
42 days 
miR9 and miR384-5p were significantly higher in mouse serum at 
3h, 12h, 24h and 72h following SCI compared to sham injured mice.  
miR219 was significantly higher in mouse serum at 3h, 12h and 24h 
following SCI compared to sham injury. 
 
 
 
    
Table 2 Biomarkers of SCI identified and/or validated using animal models 562 
Abbreviations: BBB, Basso, Beattie, Breshnahan score; CSF, cerebrospinal fluid, IVDH, intervertebral disc herniation; NF-H, neurofilament heavy chain; NSE, 563 
neuron specific enolase; GFAP, glial fibrillary acidic protein; S100β, S100 calcium binding protein β; SCI, spinal cord injury 564 
 565 
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Reference Biomarker Patient groups Sample  
numbers 
Spinal Level 
(n) 
AIS 
Grade (n) 
Age [y] 
Mean 
(Range) 
M/F ratio 
Sample/ 
Assay 
Type 
Time of 
sampling 
(post-injury) 
Findings 
Ahadi et al., 
2015 (63) 
GFAP;  
pNF-H; 
NSE 
Traumatic SCI 
 
 
 
Control (Spinal 
fracture, no 
trauma) 
n=26 
 
 
 
n=9 
C (8) 
T (8) 
L (10) 
A (10) 
B (7) 
C&D (9) 
All (n=35) 
37  
(16-64) 
30/5 
Serum/ 
ELISA 
 
 
 
24h; 
48h;  
72h 
GFAP sig. 
increased in 
trauma SCI vs 
controls at all 
time points. 
GFAP related to 
SCI severity. 
pNF-H & NSE 
sig. increased in 
trauma SCI vs 
controls at 24 & 
48h after injury. 
Biglari et al., 
2013 (89) 
sCD95L Traumatic SCI n=8 C (5) 
T (3) 
A (2) 
B (1) 
C (3) 
D (2) 
48  
(18-86) 
5/3 
Serum/ 
Immuno-assay 
24h; 
At day 3, 7, 14, 
28 & 90 
No difference 
detected between 
patients, but 
levels decreased 
during the 1
st
 
week, increased 
during the 2
nd
 
week, were 
highest in the 4
th
 
week and levels 
plateaued at 12 
weeks.  
Biglari et al., 
2015a (90) 
sCD95L Traumatic SCI n=23 C (8) 
T (9) 
L (6) 
A (15) 
B (6) 
C (2) 
43  
(18-85) 
16/7 
Serum/ 
Immuno-assay 
On admittance; 
4, 9, 12 & 24h;  
3 & 7 days; 
2, 4, 8 & 12 
weeks post-
admission 
sCD95L was 
significantly 
reduced during 
the first 24h, but 
was significantly 
higher c.f. 
admission levels 
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at 8 weeks. 
Biglari et al, 
2015b (16) 
IL-1β; 
TNF-α 
Traumatic SCI n=23 C (8) 
T (9) 
L (6) 
A (15) 
B (6) 
C (2) 
43  
(18-85) 
16/7 
Serum/ 
Immuno-assay 
On admittance; 
4, 9, 12 & 24h;  
3 & 7 days; 
2, 4, 8 & 12 
weeks post-
admission 
Improvers were 
found to have 
lower TNF-α at 
9h c.f. non-
improvers. 
IL-1β declined in 
all patients 
between 2 & 12 
weeks. 
Davies et al., 
2007 (84) 
IL-1β, IL-6, 
TNF-α, IL-4, 
IL-10, IL-2, IL-
1RA, myelin-
associated 
glycoprotein, 
GM1 
ganglioside IgG 
(G & M) 
Traumatic SCI 
 
 
 
 
Control 
n=56 
 
 
 
 
n=35 
Between 
C4 & T12 
A (14) 
B (13) 
C (22) 
D (7) 
41 
42/14 
 
 
 
35  
(18-65) 
18/17 
Serum/ 
ELISA 
1
st
 visit at rehab 
22 (2-52 wk 
post-injury) 
34 (>52 wk) 
Excluded patients 
with 
communicable 
diseases, cancer 
diagnosis or on 
anti-inflammatory 
medication also 
with nontraumatic 
aetiologies such 
as epidural 
abscess, 
aneurysm etc. 
IL-6, TNF-α, IL-
1RA & anti-GM 
was increased in 
SCI patients c.f. 
controls. 
These levels are 
increased further 
in SCI patients 
presenting with 
neuropathic pain, 
UTIs & pressure 
ulcers. 
Guez et al., 
2003 (64) 
GFAP; 
NF-L 
Cervical 
fracture 
dislocation with 
neurological 
deficit 
Severe whiplash 
with 
neurological 
deficit 
Control (no 
n=6 
 
 
n=17 
 
 
n=24 
C (6) A (3) 
B (1) 
D (2) 
48  
(40-69) 
5/1 
39  
(26-56) 
11/6 
31  
(23-56) 
12/12 
CSF/ 
ELISA 
1-21 days Exclusions 
included patients 
with head injury 
or 
unconsciousness. 
GFAP & NF-L 
increased in 
cervical fracture 
dislocation group. 
NF-L was 
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neurology) increased in 3 
patients with 
whiplash 
indicating axonal 
injury. 
Kuhle et al., 
2015 (65) 
NF-L Motor-complete 
SCI 
CCS 
 
Motor-
incomplete SCI 
Healthy controls 
(no neurological 
Deficit) 
n=13 
 
n=4 
 
n=10 
 
n=67 
C (11) 
T (2) 
C (4) 
 
C (9) 
T (1) 
 
A (12) & B (1) 
 
C (2) & D (2) 
 
C (7) & D (3) 
32  
(22-45) 
8/5 
49  
(39-62) 
3/1 
33  
(22-43) 
7/3 
35  
(28-42) 
29/38 
Serum/ 
In-house 
immuno-assay 
12h & 
every 12h 
subsequently up 
to 7days 
NF-L correlated 
with severity & 
neurological 
outcome. 
Kwon et al., 
2010 (72) 
25-plex 
cytokine array 
plus IL-16 & 
growth factors; 
Tau;  
S100β; 
GFAP 
Complete SCI 
 
Incomplete SCI 
 
Controls 
(undergoing 
operations for 
hip, knee or 
spine) 
n =14 
 
n=13 
 
n=12 
C (11) 
T (3) 
C (10) 
T (3) 
A (14) 
 
B (7) & C (6) 
All (n=27) 
48  
(20-66) 
19/8 
CSF & Serum/ 
ELISA & 
Multiplex array 
system 
≤72h 
 
Exclusions – 
concomitant head 
injuries, major 
trauma to chest, 
pelvis or 
extremities 
requiring 
intervention or if 
too sedated or 
intoxicated to 
assess neurology. 
Produced a 
biochemical 
model using a 
combination of 
S100β, GFAP & 
IL-8 from CSF to 
reliably (89% of 
patients) predict 
injury severity 
(AIS- A, B or C) 
at 24h post-injury. 
These markers 
also predicted 
segmental motor 
recovery at 6 
months. 
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Kwon et al., 
(2016) (73) 
Tau, 
S100β 
GFAP 
IL-6 
IL-8 
MCP-1 
Traumatic SCI  n=50 C (32) 
L (3) 
T (15) 
A (29) 
B (12) 
C (9) 
41.9 
4/1 
CSF/ ELISA ≤48h GFAP, IL-6, 
S100β and Tau 
were significantly 
different between 
AIS- A, B and C 
grade individuals. 
A discriminant 
function analysis 
model showed 
83% success rate 
at predicting 
baseline AIS 
grade based on 
CSF 
concentrations of 
all of these 
biomarkers  
together. Baseline 
concentrations of 
IL-6, IL-8 MCP-
1, Tau, S100β and 
GFAP were 
different between 
those who 
showed 
neurological 
improvement 
(conversion of 
AIS grade 6 
months) 
compared to those 
with the same 
AIS grade at 6 
months. 
 
Pouw et al., 
2014 (9) 
GFAP; 
NSE;  
S100β;  
Tau;  
NFH 
Motor-complete 
SCI 
Motor-
incomplete SCI 
 
n=9 
 
n=7 
C (6) 
T (3) 
C (5) 
T (2) 
A (7) 
B (2) 
C (4) 
D (3) 
All (n=16) 
46  
(18-84) 
10/6 
CSF/ 
ELISA 
≤24h Patients requiring 
interventions for 
major trauma to 
chest, pelvis 
and/or extremities 
or with pre-
existent 
neurodegenerative 
disorders were 
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excluded. 
NSE, S-100β & 
NFH were 
increased in 
motor-complete 
c.f. motor-
incomplete 
patients. 
Ungureanu et 
al., 2014 (35) 
pNF-H Complete SCI 
 
Incomplete SCI 
 
Normals 
n=8 
 
n=7 
 
n=6 
C (6) 
T (2) 
C (4) 
T (3) 
A (8) 
 
B,C, D (7) 
 
E (6) 
35  
(21-53) 
6/2 
45  
(33-59) 
5/2 
CSF/ 
ELISA 
6-12h, then 
daily until 
discharge or 
death 
Patients 
presenting with 
TBI & chronic 
CNS pathologies 
were excluded.  
pNF-H was 
detectable in all 
SCI patients, but 
was more 
elevated in 
complete SCI. 
 
Wolf et al., 2014 
(11) 
NSE; 
S100β 
Vertebral spine 
fractures with 
neurology 
deficit 
Vertebral spine 
fractures with 
no neurology 
deficit 
Control (acute 
fractured femur) 
n=12 
 
 
n=22 
 
 
n=29 
 Complete (5) 
Incomplete 
(6) 
Parasthesia 
(1) 
Spinal fracture 
(n=34) 
53  
(16-94) 
20/14 
77  
(22-94) 
8/21 
Serum/ 
Immuno-assay 
≤ 24h Patients excluded 
were those with 
TBI, requiring 
intubation or 
unstable, open 
fractures, 
pregnancy, 
polytrauma or 
severe penetrating 
injuries. 
S100β was 
increased in 
patients with 
vertebral fractures 
and was 
significantly 
highest in patients 
with neurology 
deficit. 
Yokobori et al, 
2015 (83) 
UCH-L1; 
SBDPs; 
MBP; 
GFAP 
 
Moderate-
severe SCI 
Non-SCI (with 
hydrocephalus 
or unruptured 
n=7 
 
n=15 
 A, B & C (7)  CSF & serum/ 
ELISA 
≤ 24h Preliminary data 
suggesting that 
the structural 
proteins UCH-L1 
& SBDPs may be 
 32 
aneurysm) biomarker 
candidates for 
SCI . 
 570 
Table 3 Biomarkers used in traumatic human SCI  571 
Abbreviations: CSF, cerebrospinal fluid; NF-H, neurofilament heavy chain; NSE, neuron specific enolase; GFAP, glial fibrillary acidic protein; S100β, S100 572 
calcium binding protein β; SCI, spinal cord injury; TBI, traumatic brain injury.573 
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